SCHEMBL20980930

SCHEMBL20980930

CCOCCCN1C2CCC1CC(O)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
CYP2C9 P11712 1/20 0.45
OPRM1 P35372 3/20 0.35
OPRD1 P41143 3/20 0.35
CYP2D6 P10635 2/20 0.34
RAD52 P43351 1/20 0.34
KIF11 P52732 1/20 0.34
CHRM1 P11229 2/20 0.34
CHRM2 P08172 1/20 0.34
CHRM3 P20309 1/20 0.34
SLC6A3 Q01959 3/20 0.34
SLC6A2 P23975 2/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GMNN O75496 1/20 0.33
TP53 P04637 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20698374 0.84 LMNA (0.47) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL24087139 0.81 LMNA (0.52) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL24114606 0.80 LMNA (0.42) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL24556400 0.79 LMNA (0.50) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL20739189 0.79 LMNA (0.47) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL21738651 0.78 LMNA (0.42) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL16311574 0.77 LMNA (0.56) LMNACYP2C9OPRM1OPRD1RAD52
SCHEMBL10362517 0.77 LMNA (0.56) LMNACYP2C9OPRM1OPRD1RAD52
SCHEMBL25870470 0.76 LMNA (0.40) LMNACYP2C9OPRM1OPRD1CYP2D6
SCHEMBL14967799 0.76 LMNA (0.50) LMNACYP2C9CHRM1CHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919852-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2021-02-16 US disclosed
US-20190135745-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135745-A1 IMMUNOMODULATOR COMPOUNDS IL2, FCGRT, IFNG LMNA 3957/4885CYP2C9 1815/4885OPRM1 439/4885
US-10919852-B2 Immunomodulator compounds IL2, FCGRT, IFNG LMNA 3957/4885CYP2C9 1815/4885OPRM1 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.